
Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.
Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.
The approval follows unanimous support of eli-cel's benefits in CALD from an FDA AdComm meeting and an approval for beti-cel in beta-thalassemia.
Review top news and interview highlights from the week ending September 16, 2022.
Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.
Review top news and interview highlights from the week ending September 9, 2022.
Postmortem analyses revealed cell survival and GDNF production in transplanted areas.
Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.
The chief medical officer of Passage Bio discussed research needs in FTD.
Review top news and interview highlights from the week ending September 2, 2022.
RGX-121 was well-tolerated across all 3 of the dose cohorts with no treatment-related serious adverse events reported.
Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.
The chief medical officer of Passage Bio discussed the phase 1/2 upliFT-D study of PBFT02.
Review top news and interview highlights from the week ending August 26, 2022.
The study will be carried out in Paris and is expected to begin before the end of the year.
Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.
All patients with NMOSD who received CT103A showed improved Expanded Disability Status Scale scores.
Merit Cudkowicz, MD, discussed corrected data from a phase 3 trial of NurOwn that BrainStorm believes supports a BLA submission.
Review top news and interview highlights from the week ending August 19, 2022.
Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.
The move comes after the EMA recommended an additional clinical trial of sepofarsen before applying for marketing authorization.
BrainStorm Cell Therapeutics has decided to submit a BLA for NurOwn in ALS following an erratum to a phase 3 trial.
Preclinical data showed hARSA activity levels in the brain that are predictive of functional improvements.
Review top news and interview highlights from the week ending August 12, 2022.
The 2 deaths, due to acute liver failure, occurred in patients treated in Kazakhstan and Russia.
AstroRx previously demonstrated clinically meaningful reductions in the rate of disease progression.